company background image
SPAG

Spago NanomedicalOM:SPAGO Stock Report

Market Cap

kr261.1m

7D

-3.2%

1Y

1.6%

Updated

16 Oct, 2021

Data

Company Financials +
SPAGO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SPAGO Overview

Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment.

Price History & Performance

Summary of all time highs, changes and price drops for Spago Nanomedical
Historical stock prices
Current Share Pricekr6.34
52 Week Highkr4.70
52 Week Lowkr9.44
Beta1.93
1 Month Change-7.85%
3 Month Change-3.65%
1 Year Change1.60%
3 Year Change-51.79%
5 Year Change-51.23%
Change since IPO-54.71%

Recent News & Updates

Sep 21
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

May 26
We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Mar 30
Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Spago Nanomedical AB (publ) ( STO:SPAG ) is possibly approaching a major achievement in its business, so we would like...

Shareholder Returns

SPAGOSE BiotechsSE Market
7D-3.2%3.0%4.4%
1Y1.6%17.1%29.6%

Return vs Industry: SPAGO underperformed the Swedish Biotechs industry which returned 16.7% over the past year.

Return vs Market: SPAGO underperformed the Swedish Market which returned 29.5% over the past year.

Price Volatility

Is SPAGO's price volatile compared to industry and market?
SPAGO volatility
SPAGO Beta1.93
Industry Beta0.89
Market Beta1

Stable Share Price: SPAGO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SPAGO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200717Mats Hansenhttps://spagonanomedical.se

Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

Spago Nanomedical Fundamentals Summary

How do Spago Nanomedical's earnings and revenue compare to its market cap?
SPAGO fundamental statistics
Market Capkr261.10m
Earnings (TTM)-kr26.78m
Revenue (TTM)kr7.10m

36.8x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPAGO income statement (TTM)
Revenuekr7.10m
Cost of Revenuekr11.28m
Gross Profit-kr4.18m
Expenseskr22.61m
Earnings-kr26.78m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.65
Gross Margin-58.86%
Net Profit Margin-377.35%
Debt/Equity Ratio0.0%

How did SPAGO perform over the long term?

See historical performance and comparison

Valuation

Is Spago Nanomedical undervalued compared to its fair value and its price relative to the market?

1.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPAGO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPAGO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPAGO is unprofitable, so we can't compare its PE Ratio to the Swedish Biotechs industry average.

PE vs Market: SPAGO is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPAGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPAGO is good value based on its PB Ratio (1.3x) compared to the SE Biotechs industry average (4x).


Future Growth

How is Spago Nanomedical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-11.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPAGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SPAGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SPAGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SPAGO's revenue (25.7% per year) is forecast to grow faster than the Swedish market (4.2% per year).

High Growth Revenue: SPAGO's revenue (25.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPAGO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Spago Nanomedical performed over the past 5 years?

-26.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SPAGO is currently unprofitable.

Growing Profit Margin: SPAGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPAGO is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.

Accelerating Growth: Unable to compare SPAGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPAGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9.7%).


Return on Equity

High ROE: SPAGO has a negative Return on Equity (-12.99%), as it is currently unprofitable.


Financial Health

How is Spago Nanomedical's financial position?


Financial Position Analysis

Short Term Liabilities: SPAGO's short term assets (SEK78.4M) exceed its short term liabilities (SEK7.1M).

Long Term Liabilities: SPAGO's short term assets (SEK78.4M) do not cover its long term liabilities (SEK-1,000.0).


Debt to Equity History and Analysis

Debt Level: SPAGO is debt free.

Reducing Debt: SPAGO has no debt compared to 5 years ago when its debt to equity ratio was 7.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPAGO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SPAGO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Spago Nanomedical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPAGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPAGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPAGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPAGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPAGO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Mats Hansen (50 yo)

no data

Tenure

kr1,618,000

Compensation

Dr. Mats Hansen, MSc., PhD, serves as the Chief Executive Officer of Spago Nanomedical AB (publ). Dr. Hansen has 20 years of experience from different companies in the life science industry. He served at A...


CEO Compensation Analysis

Compensation vs Market: Mats's total compensation ($USD187.91K) is below average for companies of similar size in the Swedish market ($USD268.92K).

Compensation vs Earnings: Mats's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SPAGO's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: SPAGO's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.6%.


Top Shareholders

Company Information

Spago Nanomedical AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Spago Nanomedical AB (publ)
  • Ticker: SPAGO
  • Exchange: OM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr261.096m
  • Shares outstanding: 41.18m
  • Website: https://spagonanomedical.se

Number of Employees


Location

  • Spago Nanomedical AB (publ)
  • Scheelevägen 22
  • Lund
  • Skåne County
  • 223 63
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 18:02
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.